EUVIMEDObjevte EUVIMED
FallberichtÜbersichtsarbeit

Lacosamide use during breastfeeding: A case report and a literature review

Morgan Cercos, Ines Seqat, Anthony Facile, Thierry Vial iD, Marine Auffret iD

Fundamental & Clinical Pharmacology · 2024

DOI: 10.1111/fcp.12971 ↗

At a glance

Fallbericht in Fundamental & Clinical Pharmacology, 2024. Written by Morgan Cercos and 4 co-authors. Institution: Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France. Major MEDLINE topics: Lacosamide, Breast Feeding, Anticonvulsants, Milk, Human. Cited 4 times so far (Crossref); 12 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Lacosamide, a voltage‐gated sodium channel inhibitor, is an anti‐seizure medication (ASM) from the age of 4. We report on the case of a woman treated with lacosamide for pharmacoresistant epilepsy who breastfed her infant for more than 6 months after birth. The infant's blood concentrations of lacosamide were 2.4 mg/L on Day 1 and less than 1 mg/L on Day 10 (reference values are 1–10 mg/L). No adverse drug reactions (ADRs) were reported for the infant. Eight cases of breastfeeding by mothers receiving lacosamide are described in the literature. These data confirm that a significant amount of lacosamide seems to pass into breast milk, with a relative infant dose (RID) above 20% in two cases but a low RID (1.8%) in another case. Nevertheless, blood tests, performed in two breastfed infants, revealed low concentrations of lacosamide. No ADRs were reported in eight of the breastfed infants; however, one infant, whose mother was also treated with levetiracetam, presented poor feeding and sleepiness at Day 15 of life. Given the well‐known benefits of breastfeeding for both mothers and their infants, as well as the above reassuring data, breastfeeding of healthy full‐term infants could be possible for mothers on lacosamide monotherapy. Nonetheless, relatives should be warned that data concerning the safety of lacosamide during breastfeeding are scarce and that long‐term neurodevelopment outcomes in breastfed children are unknown. Clinical monitoring of breastfed infants for drowsiness, adequate weight gain, or cutaneous rash is recommended. Additionally, the infants' serum levels should be measured in case of an unexplained adverse reaction.

Subjects

MeSH terms (MEDLINE)

LacosamideBreast FeedingAnticonvulsantsMilk, HumanHumansFemaleAdultInfantDrug Resistant EpilepsyInfant, Newborn

Author keywords

breastfeedingdrug safetyepilepsylacosamidenewbornstatus epilepticus

Substances

LacosamideAnticonvulsants

Authors and institutions

  • Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France.
  • Service de neurologie fonctionnelle et épileptologie, hôpital neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Université Lyon 1, Lyon, France.

ORCID profiles: Thierry Vial, Marine Auffret

Cite

APA

Cercos, M., Seqat, I., Facile, A., Vial, T., & Auffret, M. (2024). Lacosamide use during breastfeeding: A case report and a literature review. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12971

Vancouver

Cercos M, Seqat I, Facile A, Vial T, Auffret M. Lacosamide use during breastfeeding: A case report and a literature review. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12971

BibTeX
@article{Cercos2024,
  author = {Cercos, Morgan and Seqat, Ines and Facile, Anthony and Vial, Thierry and Auffret, Marine},
  title = {Lacosamide use during breastfeeding: A case report and a literature review},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/fcp.12971}
}
Start for free →